Real-World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study.

ABSTRACT:

Background

Janus kinase (JAK) inhibitors, filgotinib (FIL) and upadacitinib (UPA) have emerged as promising treatments for ulcerative colitis (UC). However, a comparative analysis of these JAK inhibitors, particularly in patients previously treated with tofacitinib (TOF), has not been performed.

Aims

To compare the efficacy and safety of FIL and UPA in patients with UC, including those previously exposed to TOF.

Methods

A multicentre retrospective cohort study was conducted to compare the effectiveness and safety of FIL and UPA in patients with UC whose treatment was initiated between March 2022 and December 2023. The co-primary outcomes were clinical response and remission at week 8. The secondary outcomes included treatment persistence and adverse events (AEs). Modi

SUBMITTER: Nogami A 

PROVIDER: S-EPMC11652322 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature